In the future, it may be helpful to examine survivin expression in CRC specimens, thereby identifying patients that are characterized by a poor prognostic feature and that might benefit from targeted therapies against survivin even independently of their tumor stage. The gene discussed is BIRC5; the disease is colorectal carcinoma.